In vitro and in vivo studies on vitamin E TPGS-emulsified poly(D,L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation.
This work shows a full spectrum of research on Vitamin E TPGS-emulsified Poly(D,L-lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) for paclitaxel formulation to improve its therapeutic index and to reduce the adverse effects of adjuvant Cremophor EL in its current clinical formulation of Taxol. Paclitaxel-loaded PLGA NPs were prepared by a modified solvent extraction/evaporation technique with vitamin E TPGS as emulsifier. The formulated NPs were found in quite uniform size of approximately 240 nm diameter. The in vitro drug release profile exhibited a biphasic pattern with an initial burst followed by a sustained release. In vitro HT-29 cell viability experiment demonstrated that the drug formulated in the NPs was 5.64, 5.36, 2.68, and 1.45 times more effective than that formulated in the Taxol formulation after 24, 48, 72, 96 h treatment, respectively at 0.25 microg/mL drug concentration, which should be even better with the sustainable release feature of the NPs formulation considered. In vivo PK measurement confirmed the advantages of the NP formulation versus Taxol. The area-under-the-curve (AUC) for 48 h for Vitamin E TPGS emulsified PLGA NP formulation of paclitaxel were found 3.0 times larger than that for the Taxol formulation. The sustainable therapeutic time, at which the drug concentration drops below the minimum effective value, for the NP formulation could be 1.67 times longer than that for the Taxol formulation.
Win
Khin Yin
KY
Faculty of Engineering, Department of Chemical & Biomolecular Engineering, National University of Singapore.
Feng
Si-Shen
SS
D000972:Antineoplastic Agents, Phytogenic / Q000737:chemistry / Q000493:pharmacokinetics*; D019540:Area Under Curve; D004337:Drug Carriers; D016503:Drug Delivery Systems; D045703:Emulsifying Agents / Q000737:chemistry / Q000378:metabolism*; D005990:Glycerol / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry / Q000378:metabolism*; D049329:Nanostructures; D017239:Paclitaxel / Q000737:chemistry / Q000493:pharmacokinetics*; D011092:Polyethylene Glycols / Q000737:chemistry / Q000378:metabolism; D011100:Polyglycolic Acid / Q000737:chemistry / Q000378:metabolism*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000737:chemistry / Q000378:metabolism*; D013501:Surface-Active Agents / Q000009:adverse effects; D014810:Vitamin E / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism
D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D045703:Emulsifying Agents; D011108:Polymers; D013501:Surface-Active Agents; D014810:Vitamin E; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D011092:Polyethylene Glycols; C000515:cremophor EL; C014225:tocophersolan; D017239:Paclitaxel; D005990:Glycerol